Cipla

Leuprollide Depot

Manufacturer:

Cipla

Leuprollide Depot HCPCS:

J1954

HCPCS Code Descriptor:

Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg

Category:

J Code

Leuprollide Depot NDCs:

69097-0909-50

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Leuprollide Depot:

Leuprollide Depot is an Oncology drug manufactured by Cipla and administered via the Intramuscular route of administration. The J Code: J1954 is aligned to the drug Leuprollide Depot.

ACCESS PRICING AND MORE BY REGISTERING

J1954 Added Date:

January 1, 2023

J1954 Effective Date:

April 1, 2023

J1954 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Leuprollide Depot billing and coding information.
Our team did not identify a source for Leuprollide Depot patient assistance information. Please reach out to our team if you feel that this is a mistake.
Leuprollide Depot prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for Leuprollide Depot. Please check back in a few weeks.